A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders
S. T. Wilkinson, Mesut Toprak, Mason S. Turner, Steven P. Levine, Rachel B. Katz, Gerard Sanacora
American Journal of Psychiatry July 1, 2017 DOI: 10.1176/appi.ajp.2017.17020239 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Randomized Peer reviewed |
|---|---|
| Topics | Esketamine Ketamine |
| Key points | Notes that small randomized controlled trials since 2000 show ketamine has potent, rapid antidepressant effects in treatment-resistant depression, and that despite limited long-term data and no FDA indication, many providers now offer ketamine treatment. States that the practice patterns of these providers have not been studied. |
Abstract
TO THE EDITOR: Since 2000, several small randomized controlled trials have demonstrated that ketamine has potent and rapid-acting antidepressant effects in patients with treatment-resistant depression (1). Despite a lack of longterm data or Food and Drug Administration indication, many community providers and academic centers have begun offering ketamine treatment to patients with major depressive disorder and with other psychiatric disorders, determining the existing evidence justifies use for some individuals. Thepractice patterns of suchprovidershavenot been studied.
Citations in the library
Cited by 66
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- Ketamine: a paradigm shift for depression research and treatment Neuron March 1, 2019
- Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective Psychiatry and Clinical Neurosciences June 19, 2019
- Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide F1000Research May 24, 2018
- Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites Translational Psychiatry November 7, 2019
and 61 more in the library
Cites 3
- Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression American Journal of Psychiatry October 1, 2015
- A REVIEW OF KETAMINE ABUSE AND DIVERSION Depression and Anxiety August 1, 2016
- Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction January 2010